论文部分内容阅读
探讨Ｏ６┐甲基鸟嘌呤┐ＤＮＡ甲基转移酶（ＭＧＭＴ）表达与脑肿瘤对氯乙基亚硝脲（ＣＥＮＵｓ）耐药的关系。方法采用Ｗｅｓｔｅｒｎｂｌｏｔ方法检测５９例不同类型脑肿瘤组织ＭＧＭＴ蛋白表达水平，对其中３０例胶质瘤同时采用ＲＴ┐ＰＣＲ检测其ＭＧＭＴｍＲＮＡ表达水平，ＭＧＭＴｍＲＮＡ表达水平与ＭＧＭＴ活性进行相关分析。结果ＭＧＭＴｍＲＮＡ表达水平与ＭＧＭＴ活性正相关（ｒ＝０．９１１，Ｐ＜０．０１），非胶质瘤及转移癌ＭＧＭＴ蛋白表达阳性率明显较胶质瘤高，分别为９０％，７８％，７％（Ｐ＜０．０５）；不同个体胶质瘤ＭＧＭＴｍＲＮＡ表达有较大异质性，范围为０～１．２９，平均为０．５±０．３７，Ｍｅｒ－率为３７％；高、低级别星形细胞瘤ＭＧＭＴｍＲＮＡ表达无差异（０．４７±０．３６和０．４４±０．３４）；髓母细胞瘤有较高的ＭＧＭＴｍＲＮＡ表达水平（０．８０）。结论胶质瘤ＭＧＭＴ总体水平较低，为此ＣＥＮＵｓ作为化疗首选药提供了新的理论依据；但半数以上胶质瘤为Ｍｅｒ＋表型，提示对ＣＥＮＵｓ耐药，因而化疗前检测Ｍｅｒ表型以筛选Ｍｅｒ－个体进行化疗将进一步提高疗效。
To investigate the relationship between the expression of methylguanine methylguanine methyltransferase (MGMT) and the resistance of brain tumor to CENUs. Methods Western blot was used to detect the expression of MGMT protein in 59 cases of different types of brain tumors. The expression of MGMT mRNA was detected by RT PCR in 30 gliomas at the same time. The correlation between MGMT mRNA expression and MGMT activity was analyzed. Results The positive expression rate of MGMT mRNA was positively correlated with MGMT activity (r = 0.911, P <0.01). The positive rates of MGMT protein in non-glioma and metastatic MGMT were significantly higher than those in gliomas (90%, 78% 7% (P <0.05). The MGMT mRNA expression in different individual gliomas was highly heterogeneous, ranging from 0 to 1.29 with an average of 0.5 ± 0.37 and a Mer-rate of 37% (0.47 ± 0.36 and 0.44 ± 0.34) in low-grade astrocytomas, and higher MGMT mRNA expression in medulloblastoma (0.80). Conclusions The overall level of MGMT in glioma is relatively low. Therefore, CENUs provide a new theoretical basis for the chemotherapeutic drug of choice. However, more than half of the gliomas are Mer + phenotype, which suggests resistance to CENUs. Therefore, Mer phenotype was detected before screening for screening Mer - individual chemotherapy will further improve the efficacy.